MET and non-small cell lung carcinoma: Despite the development of acquired MET mutations seems to be related to the type of MET-inhibitors, at present, no clinical trial has been designed to investigate the re-sensitiveness of these patients to a novel class of MET TKIs, with the exception of a small phase II trial of capmatinib in crizotinib-resistant NSCLC patients, which showed discouraging results [128].